Results: We tested 1,249 individuals for HCV from December 2012 to February 2014. Anti-HCV seroprevalence was 4.2% (n =52). Ninety-two percent (n=48) of patients with a reactive antibody test accepted an offer for same-day phlebotomy; 81% (n=42) had successful confirmatory testing performed. We contacted 98% (n=41) of patients with their confirmatory test results. Sixty-nine percent (n=36) of anti-HCV positive patients had detectable HCV RNA. Thirty-six percent (n=13) FK866 mw of chronically infected patients were uninsured, 62% (n=8) have since obtained insurance and a primary care provider (PCP). With case management, 64% (n=23) of chronically infected patients obtained

a referral to an HCV subspecialist and 58% (n=21) were linked to subspecialty care. Obtaining a referral for sub-specialty care, even with assistance of a patient navigator, was a barrier for 26% (n=8) of individuals who had a PCP. Treatment and SVR outcomes are forthcoming. Conclusions: Utilizing same day phlebotomy for confirmatory testing in community based programs is an effective means for improving the HCV cascade of care. Obtaining a referral to an HCV subspecialist is an obstacle for individuals diagnosed in community

based testing programs. Aggressive patient navigation services can reduce barriers and enhance outcomes for linkage and retention of HCV positive selleck kinase inhibitor individuals in care. Disclosures: Stacey B. Trooskin – Advisory Committees or Review Panels: Gilead Sciences; Grant/Research Support: Gilead Sciences Amy Nunn – Consulting: Mylan; Grant/Research Support: Gilead The following people

have nothing to disclose: Hwajin Lee, Joanna Poceta, Caitlin Towey, Sophie C. Feller, Annajane Yolken, Najia Luqman, Ta-Wanda Preston, Erin Smith Background: HCV genotypes are clinically important for predicting the response to and determining the duration of therapy. Especially with the advent of new DAAs demonstrating that these regimens MCE公司 depend on the HCV genotypes, determining genotypes is very important. Some studies indicated that using the 5′NC region to define HCV genotypes led to mis-classification of genotype 6 into genotype 1. These errors were not seen when using NS5B or core regions. Aim: – Identify HCV genotypes using 5′NC and NS5B regions. -Confirm previous studies that indicated mis- classification of HCV genotypes using 5′NC. – Establish prevalence of HCV genotypes using NS5B. Methods: This was a retro- sectional study. We studied 3 groups of patients: Group I included 3686 patients using 5′NC region (male 48.86%, female 51,14% with mean age of patients 49.20 ± 11.48 from January 2007 to August 2011); Group II included 176 patients using NS5B (male 43.19%, female 56.81% with mean age of patients 50.01 ± 8.63 from August 2013 to May 2014); Group III included 101 patients with genotype 1 using 5′NC who were randomly genotyped again by using NS5B (male 41.58%, female 58.42% with mean age of patients 53.12 ± 11.02 from August 2013 to April 2014).